Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

Buffalo Wild Wings nabs Marcato nominee for own director slate

Mar 27, 2017

US-BUFFALO-WILD-MARCATO:Buffalo Wild Wings nabs Marcato nominee for own director slate

PepsiCo to close British plant, threatening nearly 400 jobs

Mar 1, 2017

US-PEPSICO-BRITAIN-JOBS:PepsiCo to close British plant, threatening nearly 400 jobs

Indonesia tobacco bill would fire up output despite health fears

Mar 15, 2017

US-INDONESIA-TOBACCO:Indonesia tobacco bill would fire up output despite health fears

Must Read

Buffalo Wild Wings nabs Marcato nominee for own director slate

Mar 27, 2017

US-BUFFALO-WILD-MARCATO:Buffalo Wild Wings nabs Marcato nominee for own director slate

PepsiCo to close British plant, threatening nearly 400 jobs

Mar 1, 2017

US-PEPSICO-BRITAIN-JOBS:PepsiCo to close British plant, threatening nearly 400 jobs

Indonesia tobacco bill would fire up output despite health fears

Mar 15, 2017

US-INDONESIA-TOBACCO:Indonesia tobacco bill would fire up output despite health fears

Search
Top News
You May Need To Know

About Us

Travel Leisure Mag is New York City’s travel and lifestyle online magazine with the vision of creating a unique blend of valuable and quality travel experience to the readers. We trust that you will enjoy this experience.

Contact us: sales@travelleisuremag.com